| abstract |
REFERS TO A PHARMACEUTICAL COMPOSITION CONTAINING: A) AN INHIBITOR OF SPHINGOSINE-1-PHOSPHATE (S1P) LIASASE SUCH AS THE COMPOUNDS OF FORMULA (I) WHERE R1 IS H, ALKYL (C1-C20) OR ARYL; R3 IS H, OR3A, NHC (O) R3A, AMONG OTHERS, WHERE R3A IS H, (C1-C20) ALKYL, AMONG OTHERS; R6 IS OR6A OR OC (O) R6A; R7 IS OR7A OR OC (O) R7A; R8 IS OR8A OR OC (O) R8A; R9 IS H, CH2OR9A OR CH2OC (O) R9A, WHERE R6A, R7A, R8A AND R9A ARE H OR LOWER ALKYL (C1-C4); BEING A PREFERRED COMPOUND (E) -1- (4 - ((1R, 2S, 3R) -1,2,3,4-TETRAHYDROXIBUTYL) -1H-IMIDAZOL-2-IL) -ETANONE OXYME; AND B) AN ACTIVE AGENT SELECTED FROM i) AN ANTI-MALARIA DRUG SUCH AS QUININE, QUINIDINE, AMONG OTHERS, ii) AN OSMOTIC DIURETIC SUCH AS MANNITOL OR UREA, iii) AN ANTI-CONVULSIVANT SUCH AS DIAZEPAN, PHENIDINE, iv) BETWEEN OTHERS ANTIPIRETIC SUCH AS PARACETAMOL, v) AN ANTIOXIDANT, OR vi) AN ANTI-INFLAMMATORY SUCH AS AN NSAID, INFLIXIMAB, AMONG OTHERS. SUCH COMPOSITION IS USEFUL TO TREAT, MANAGE AND / OR PREVENT CEREBRAL MALARIA |